Dated biotech events, next seven days

3 events, 0 on a confirmed date. Every row carries the filing, release or registry record its date was read from, and how precise that date is. Nothing here is a recommendation and no price appears on this page.

This list rolls forward every day. The desk holds the full table, filters and the research probability on each row.

Dated biotech events for 21–27 September 2026, with the source behind each date.
CompanyEventDateValue at stakeCash to the dateSource
Tuesday 1 September
ARGXARGENX SEPhase 3 toplinePrimary completion of A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor NeuropathyEmpasiprubart2026-09Estimatedopens with a free accountno filed issuer facts yetfinancing on file, through 18 Sep 2026
  • ClinicalTrials.gov, read 21 Sep 2026“primaryCompletionDateStruct: {"date": "2026-09", "type": null}”
RGNXREGENXBIO Inc.Phase 3 toplinePrimary completion of AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)RGX-2022026-09Estimatedopens with a free accountno filed issuer facts yetfinancing on file, through 18 Sep 2026
  • ClinicalTrials.gov, read 21 Sep 2026“primaryCompletionDateStruct: {"date": "2026-09", "type": null}”
VNDAVanda Pharmaceuticals Inc.Phase 3 toplinePrimary completion of Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)Tasimelteon2026-09Estimatedopens with a free accountno filed issuer facts yetfinancing on file, through 18 Sep 2026
  • ClinicalTrials.gov, read 21 Sep 2026“primaryCompletionDateStruct: {"date": "2026-09", "type": null}”

Oldest input as of 2026-09-21. Composed 21 Sep 2026 · event table maintained 21 Sep 2026. Assembling this page is not evidence that the sources under it were re-read.